Pulished Date October, 2018
ID: 890
Share on
Share on

North America Liquid Biopsy Market By Cancer Type (Lung Cancer, Pancreatic Cancer, Leukemia And Other Visceral Cancers) By Sample Type (Blood, Urine, Plasma, Saliva And Cerebrospinal) By Diagnostic Approach (Circulating Tumour Cells (CTC), Circulating Tumour DNA (ctDNA), RNA In Exosomes And Extra-Cellular Vesicles), By End Users (Reference Laboratories, Hospital/Physician Laboratories, Academic And Research Centers, And Other End Users) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: October, 2018
ID: 890
Pages: 145

The North America Liquid Biopsy market is expected to increase at a CAGR of 19.6% in the forecast period of 2018-2023 and reach a value of USD 599.57 million by 2021 from USD 245.01 million in 2018. North America is leading market for Liquid Biopsy. Liquid biopsy market is on high growth in North America as colorectal cancer stands fourth most common diagnosed cancer in the region. There is a lot of research going on for the detection of colorectal cancer. Geographically North America Market is segmented into USA and Canada.

Liquid Biopsy is an emerging non-invasive procedure that can detect cancer at very advance stage. This is done by testing a sample of blood and detecting cancer cells from the tumour. Taking various samples of the blood helps doctors understand the behaviour of the tumour over time. This technique of detecting cancer is very valuable for the doctors using targeted therapies to treat cancer.

Rising demand for non-invasive procedures, greater accuracy to detect cancer cells and the increasing number of cancer cases are the key factors driving the liquid biopsy market. However, the unclear regulatory and reimbursement scenario is a major area of concern in the market.

The liquid biopsy market is mainly segmented by types of cancer into Lung Cancer, Pancreatic Cancer, Leukemia and Other Visceral Cancers. By Diagnostic approach they can be classified as Circulating Tumour cells (CTC), Circulating Tumour DNA (ctDNA), RNA in exosomes and Extra-Cellular Vesicles. Based on end users, the market is segmented into reference laboratories, hospital/physician laboratories, academic and research centers, and other end users. The market is bifurcate into blood, urine, plasma, saliva and Cerebrospinal fluid based upon sample type. CTCs (Circulating Tumour cells), the first such entities on the liquid biopsy scene, have accounted for a large share in the market. Cancer institute is the largest end user segment in terms of revenues and is expected to create substantial opportunity in global liquid biopsy market over the forecast period.     

The key players dominating the liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Cancer Type                                         

                                5.1.1 Lung Cancer                           

                                5.1.2 Pancreatic Cancer                

                                5.1.3 Leukemia                

                                5.1.4 Other Visceral Cancers                       

                5.2 By Sample Type                                        

                                5.2.1 Blood                        

                                5.2.2 Urine                         

                                5.2.3 Plasma                      

                                5.2.4 Saliva                         

                                5.2.5 Cerebrospinal                        

                5.3 By Diagnostic Approach                                        

                                5.3.1 Circulating Tumour cells (CTC)                        

                                5.3.2 Circulating Tumour DNA (ctDNA)                  

                                5.3.3 RNA in exosomes                 

                                5.3.4 Extra-Cellular Vesicles                        

                5.4 By End Users                                             

                                5.4.1 Reference Laboratories                     

                                5.4.2 Hospital/Physician Laboratories                     

                                5.4.3 Academic and Research Centers                    

                                5.4.4 Other End Users                   

6. Geographical Analysis                                                              

                                6.1 Introduction                              

                                6.2 United States                            

                                6.3 Canada                         

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 Janssen Diagnostics                                

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Qiagen                                         

                8.3 Rarecells SAS                                             

                8.4 Silicon Biosystems                                   

                8.5 SRI International                                      

                8.6 Myriad Genetics                                      

                8.7 Natera                                          

                8.8 Personal Genome Diagnostics                                            

                8.9 Sysmex Inostics                                        

                8.10 Trovagene                                

                8.11 Exosome Diagnostics                                           

                8.12 HansaBiomed OU                                  

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Liquid Biopsy Market By Region, From 2018-2023(USD Million)
  2. North America Liquid Biopsy Market By Cancer Type, From 2018-2023(USD Million)
  3. North America Lung Cancer Market By Region, From 2018-2023(USD Million)
  4. North America Pancreatic Cancer Market By Region, From 2018-2023(USD Million)
  5. North America Leukemia Market By Region, From 2018-2023(USD Million)
  6. North America Other Visceral Cancers Market By Region, From 2018-2023(USD Million)
  7. North America Liquid Biopsy Market By Sample Type, From 2018-2023(USD Million)
  8. North America Blood Market By Region, From 2018-2023(USD Million)
  9. North America Urine Market By Region, From 2018-2023(USD Million)
  10. North America Plasma Market By Region, From 2018-2023(USD Million)
  11. North America Saliva Market By Region, From 2018-2023(USD Million)
  12. North America Cerebrospinal Market By Region, From 2018-2023(USD Million)
  13. North America Liquid Biopsy Market By Diagnostic Approach, From 2018-2023(USD Million)
  14. North America Circulating Tumour cells (CTC) Market By Region, From 2018-2023(USD Million)
  15. North America Circulating Tumour DNA (ctDNA) Market By Region, From 2018-2023(USD Million)
  16. North America RNA in exosomes Market By Region, From 2018-2023(USD Million)
  17. North America Extra-Cellular Vesicles Market By Region, From 2018-2023(USD Million)
  18. North America Liquid Biopsy Market By End Users, From 2018-2023(USD Million)
  19. North America Reference Laboratories Market By Region, From 2018-2023(USD Million)
  20. North America Hospital/Physician Laboratories Market By Region, From 2018-2023(USD Million)
  21. North America Academic and Research Centers Market By Region, From 2018-2023(USD Million)
  22. North America Other End Users Market By Region, From 2018-2023(USD Million)
  23. United States Liquid Biopsy Market By Cancer Type, From 2018-2023(USD Million)
  24. United States Liquid Biopsy Market By Sample Type, From 2018-2023(USD Million)
  25. United States Liquid Biopsy Market By Diagnostic Approach, From 2018-2023(USD Million)
  26. United States Liquid Biopsy Market By End Users, From 2018-2023(USD Million)
  27. Canada Liquid Biopsy Market By Cancer Type, From 2018-2023(USD Million)
  28. Canada Liquid Biopsy Market By Sample Type, From 2018-2023(USD Million)
  29. Canada Liquid Biopsy Market By Diagnostic Approach, From 2018-2023(USD Million)
  30. Canada Liquid Biopsy Market By End Users, From 2018-2023(USD Million)

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients